Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Drugs Global Market Report 2024

The cyclin-dependent kinase (cdk) 4/6 inhibitor drugs market size has grown exponentially in recent years. It will grow from $10.18 billion in 2023 to $12.35 billion in 2024 at a compound annual growth rate (CAGR) of 21.3%. The growth observed in the historic period can be attributed to several factors, including the increasing incidence of cancer, clinical success stories showcasing the efficacy of CDK 4/6 inhibitors, a growing aging population, and heightened awareness leading to early diagnosis. These factors collectively contributed to the historical expansion of the use of CDK 4/6 inhibitor drugs in breast cancer treatment.

The cyclin-dependent kinase (cdk) 4/6 inhibitor drugs market size is expected to see rapid growth in the next few years. It will grow to $25.17 billion in 2028 at a compound annual growth rate (CAGR) of 19.5%. The anticipated growth in the forecast period can be attributed to various factors, including the expansion of indications for CDK 4/6 inhibitors, the emergence of new pipeline molecules, the impact of market competition and pricing dynamics, the adoption of personalized medicine approaches, and improvements in global healthcare infrastructure. Major trends expected in the forecast period include advancements in biomarker identification, the rise of oral CDK 4/6 inhibitors, the exploration of CDK 4/6 inhibitors in other cancer types, efforts focused on overcoming resistance mechanisms, and an increase in clinical trials exploring novel CDK 4/6 inhibitors.

The anticipated increase in the prevalence of breast cancer is poised to drive the growth of the cyclin-dependent kinase (CDK) 4/6 inhibitor drug market. Breast cancer, originating in breast cells, prompts the demand for targeted therapies such as CDK4/6 inhibitors, addressing specific types of breast cancer and contributing to managing the escalating prevalence of the disease. As reported by the American Cancer Society in January 2023, breast cancer cases surged from 284,200 in 2021 to 300,590 in 2023, marking a significant increase of 5.76%. Consequently, the rising prevalence of breast cancer is forecasted to be a pivotal driver propelling growth within the cyclin-dependent kinase (CDK) 4/6 inhibitor drug market.

The augmented investment in research and development endeavors for breast cancer treatment is expected to significantly boost the cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market. The increased funding in breast cancer treatment facilitates the innovation and expansion of CDK4/6 inhibitor drugs, enhancing their efficacy and broadening their applications, thereby fostering market expansion. For instance, Susan G. Komen, a reputable US-based breast cancer organization, allocated $21.7 million in June 2022 to sponsor 48 novel research initiatives at 26 esteemed academic medical institutions across the United States. These initiatives aim to enhance patient outcomes, particularly for individuals grappling with aggressive forms of breast cancer or facing recurrence or metastasis. Hence, the amplified investment in research and development for breast cancer treatment emerges as a key factor driving the growth of the cyclin-dependent kinase (CDK) 4/6 inhibitor drug market.

The distinctive array of side effects associated with cyclin-dependent kinase (CDK) 4/6 inhibitor drugs presents a challenge that could potentially impede the market's growth in the forecast period. Among these side effects, neutropenia stands out, marked by a decrease in white blood cells that elevates the risk of infections. This condition is transient and dosage-dependent, typically resolving when the drug dose is adjusted or temporarily halted. According to the National Library of Medicine in June 2023, the most prevalent side effect of CDK 4/6 inhibitors was neutropenia, with rates of occurrence at 80% for palbociclib, 75% for ribociclib, and 41% for abemaciclib. Consequently, the incidence of these side effects poses a hindrance to the growth of the cyclin-dependent kinase (CDK) 4/6 inhibitor drug market.

Major companies operating within the cyclin-dependent kinase (CDK) 4/6 inhibitor drug market are directing their efforts toward the development of advanced therapies, notably combination therapies, aiming to further enhance the treatment landscape for patients, address unmet medical needs, and optimize patient outcomes. Combination therapies involve the simultaneous use of two or more diverse treatment modalities or drugs, aiming to augment the effectiveness of medical interventions. For instance, in October 2021, Eli Lilly and Company, a leading US-based pharmaceutical developer and manufacturer, obtained approval from the U.S. Food and Drug Administration (FDA) for Verzenio (abemaciclib) as the first and sole CDK4/6 inhibitor used in combination with endocrine therapy (such as tamoxifen or an aromatase inhibitor). This combination therapy is intended for the adjuvant treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, early breast cancer (EBC) at a high risk of recurrence and with a Ki-67 score of 20%. This tailored treatment option represents a significant advancement offering improved outcomes for individuals in need of more effective therapeutic approaches.

In July 2022, Pfizer Inc., a renowned US-based pharmaceutical company specializing in CDK4/6 inhibitor drugs, embarked on a collaboration with Arvinas Inc., a prominent biopharmaceutical company also based in the United States. Their joint objective involves the development and commercialization of ARV-471, an investigative oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. This partnership is geared towards addressing the treatment needs of patients coping with locally advanced or metastatic breast cancer. Pfizer Inc. intends to synergize its expertise in CDK4/6 inhibitor drugs to maximize the therapeutic potential and effectiveness of ARV-471 in treating this challenging medical condition.

Major companies operating in the cyclin-dependent kinase (cdk) 4/6 inhibitor drugs market report are Pfizer Inc., Merck & Co. Inc., Novartis AG, Bristol Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Gilead Sciences Inc, Incyte Corporation, Jiangsu Hengrui Pharmaceuticals Co. Ltd., Dr. Reddy’s Laboratories Ltd, Piramal Group, Hanmi Pharm Co. Ltd., Incepta Pharmaceuticals Ltd, Beacon Pharmaceuticals PLC, Bluepharma, Astex Pharmaceuticals, Arvinas Inc , G1 Therapeutics Inc., Carisma Therapeutics Inc., Beta Pharma Inc., Syros Pharmaceuticals Inc., Cyclacel Pharmaceuticals Inc., Onconova Therapeutics Inc., Context Therapeutics Inc., NanoDaru.

North America was the largest region in the cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market in 2023. The regions covered in the cyclin-dependent kinase (cdk) 4/6 inhibitor drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa The countries covered in the cyclin-dependent kinase (cdk) 4/6 inhibitor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The cyclin-dependent kinase (CDK) 4/6 inhibitor drug market consists of sales of trilaciclib and ramiven drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The primary CDK 4/6 inhibitor drugs include palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio). Palbociclib, for instance, is a targeted therapy medication designed for treating hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer. It is often utilized in combination with endocrine therapy, offering an effective treatment option for patients with advanced or metastatic breast cancer. These drugs cater to various patient groups, such as premenopausal, postmenopausal, and others. The end users encompass hospitals, clinics, research laboratories, and retail pharmacies.

The cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market research report is one of a series of new reports that provides cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market statistics, including cyclin-dependent kinase (CDK) 4/6 inhibitor drugs industry global market size, regional shares, competitors with a cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market share, detailed cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the cyclin-dependent kinase (CDK) 4/6 inhibitor drugs industry. This cyclin-dependent kinase (CDK) 4/6 inhibitor drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future- scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.